Inhibrx Biosciences, Inc.
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated…
